Table 3. Median PFS and OS of MM patients depending on selected factors.

Variable	Progression free survival		Overall survival
	Median (months)	p HR (95% CI)	Median (months)	p HR (95% CI)
	15		79
Sex
Men	12	0,6938	50	0,0585
Women	15	0,89 (0,50-1,61)	79	2,45 (1,06-5,63)
Age
<65	15	0,5942	82	0,2853
≥65	17	0,85 (0,44-1,64)	38	0,63 (0,23-1,70)
Smoking
Non-smokers	12	0,8644	79	0,6341
Active and ex-smokers	15	0,95 (0,52-1,73)	103	1,23 (0,50-2,99)
Exposure to carcinogenic factors
Yes	21	0,7515	79	0,5778
No	10	0,91 (0,51-1,63)	-	1,25 (0,55-2,86)
Family history of cancer
Yes	19	0,5949	103	0,0662
No	10	0,86 (0,49-1,52)	50	0,45 (0,20-1,02)
History of other cancers
Yes	11	0,8036	79	0,7547
No	15	1,19 (0,26-5,51)	82	0,73 (0,13-4,17)
Diagnosis
Secretory
Light chain disease	15		79
Non-secretory/plasmablastic type	11	0,7947	103	0,7487
Non-secretory/plasmacytoma		1,10 (0,54-2,22)		0,85 (0,30-2,41)
Monoclonal protein class
IgA	17	0,2375	38	0,4391
IgG	12	0,69 (0,37-1,31)	79	1,43 (0,53-3,85)
Light chain type
Lambda	11	0,2281	56	0,1122
Kappa	21	1,40 (0,75-2,61)	103	1,90 (0,79-4,57)
Durie-Salmon stage
I, II	7	0,7786	82	0,6610
III	16	1,17 (0,33-4,12)	79	1,24 (0,43-3,58)
ISS stage
1, 2	24	0,2258	82	0,0338
3	11	0,62 (0,31-1,25)	38	0,42 (0,18-0,99)
Deletion 17p
Present	10	0,7788	-	0,8796
Absent	10	0,89 (0,37-2,09)	50	1,10 (0,29-4,15)
Translocation t(4;14)
Present	5	0,0619	33	0,0453
Absent	12	2,28 (0,69-7,56)	56	2,99 (0,59-15,10)
Translocation t(4;16)
Present	9	0,5061	-	0,6176
Absent	12	1,91 (0,13-28,67)	50	-
Renal function
A	17	0,1250	82	0,0136
B	8	0,55 (0,20-1,52)	33	0,34 (0,09-1,27)
Stage of chronic kidney disease
G1/G2	18	0,5056	82	0,0572
G3a/G3b/G4/G5D	8	0,83 (0,44-1,56)	38	0,46 (0,17-1,22)
Performance status
0, 1	12	0,7900	82	0,1958
2, 3	16	1,08 (0,61-1,90)	79	0,58 (0,26-1,33)
Body weight loss before treatment
Yes	10	0,1082	56	0,0028
No	18	1,55 (0,86-2,81)	103	3,32 (1,42-7,77)
Anemia grade before treatment (WHO)
Absent or Io	21	0,0086	103	0,0002
IIo, IIIo or IVo	8	0,49 (0,26-0,93)	38	0,24 (0,09-0,60)
HGB
Normal	37	0,0235	103	0,1238
Low	10	0,40 (0,21-0,76)	79	0,35 (0,13-0,94)
PLT
Normal	17	0,2227	103	0,0306
Low	10	0,68 (0,34-1,38)	38	0,42 (0,15-1,13)
ALB
Normal	21	0,1835	103	0,0237
Low	9	0,70 (0,39-1,24)	56	0,40 (0,17-0,93)
CRP
Normal	18	0,7406	82	0,0456
High	11	0,91 (0,50-1,66)	38	0,44 (0,18-1,06)
LDH
Normal	12	0,9448	79	0,3383
High	16	0,97 (0,38-2,49)	-	2,52 (0,64-9,85)
Calcium
Normal	17	0,7698	79	0,7630
High	8	1,09 (0,58-2,07)	-	0,87 (0,33-2,28)
B2M
Normal	21	0,1327	82	0,0180
High	10	0,66 (0,36-1,19)	38	0,37 (0,16-0,88)
Creatinine
Normal	19	0,3620	82	0,0617
High	9	0,77 (0,42-1,42)	56	0,47 (0,19-1,15)
eGFR
Normal	18	0,7928	82	0,1897
Low	10	1,07 (0,61-1,89)	56	0,59 (0,26-1,34)
Genotype CRBN (rs6768972)
AA	18	0,0062	82	0,7984
AC or CC	9	0,49 (0,26-0,91)	-	0,90 (0,39-2,07)
Genotype CRBN (rs6768972)
AC	10	0,0179	38	0,2847
AA or CC	17	1,89 (1,00-3,56)	82	1,52 (0,64-3,62)
Genotype CRBN (rs6768972)
CC	8	0,1812	-	0,1682
AA or AC	16	2,42 (0,28-20,74)	79	-
Genotype CRBN (rs1672753)
CC	4	0,0321	-	0,5579
CT or TT	16	3,93 (0,26-59,64)	79	0,56 (0,12-2,63)
Genotype CRBN (rs1672753)
CT	15	0,7318	103	0,5232
CC or TT	12	1,10 (0,62-1,95)	82	1,30 (0,57-2,96)
Genotype CRBN (rs1672753)
TT	16	0,4248	79	0,7397
CC or CT	12	0,79 (0,45-1,41)	103	0,87 (0,37-2,01)